These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20164673)

  • 21. [Treatment of metastatic renal cell carcinoma].
    Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
    Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
    Biró K; Küronya Z
    Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Gschwend J; Jäger E; Keilholz U
    Aktuelle Urol; 2010 May; 41(3):193-6. PubMed ID: 20486036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Gschwend JE
    Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Present state of target therapy for disseminated renal cell carcinoma.
    Waalkes S; Kramer M; Herrmann TR; Schrader AJ; Kuczyk MA; Merseburger AS
    Immunotherapy; 2010 May; 2(3):393-8. PubMed ID: 20635903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of targeted therapies for renal cell cancer].
    Merseburger AS; Kuczyk MA
    Urologe A; 2008 Oct; 47(10):1303-10. PubMed ID: 18587556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK; Papadopoulos G
    J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 30. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
    Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
    Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
    Bergmann L
    Onkologie; 2010; 33 Suppl 1():2-4. PubMed ID: 20164668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S; Choueiri TK
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK; Rini BI
    Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Targeted therapies: sequential and combined treatments].
    Gross-Goupil M; Escudier B
    Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.
    Cersosimo RJ
    Am J Health Syst Pharm; 2009 Sep; 66(18):1625-33. PubMed ID: 19729567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced kidney cancer: treating the elderly.
    Zustovich F; Novara G
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1389-98. PubMed ID: 24224483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.